

Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients

Matt Williams^{*a,b}, Kerlann Le Calvez^{a,b}, Ella Mi^b, Jiarong Chen^a, Seema Dadhanian^{a,b}, Lillie Pakzad-Shahabi^c

^aComputational Oncology Group, Imperial College London

^bDepartment of Radiotherapy, Imperial College Healthcare Trust

^cJohn Fulcher Neuro-oncology Lab, Imperial College London

<https://doi.org/10.33697/ajur.2019.003>

Email: matthew.williams@imperial.ac.uk

KEYWORDS

COVID; Cancer; Chemotherapy; Risk

Abstract

The SARS-CoV-2 (COVID-19) novel corona virus represents a significant health risk, particularly in older patients. Cancer is one of the leading causes of death in most rich countries, and delivering chemotherapy may be associated with increased risk in the presence of a pandemic infection. Estimating this risk is crucial in making decisions about balancing risks and benefits from administering chemotherapy. However, there are no specific data about chemotherapy risks per se. Here we develop a simple model to estimate the potential harms in patients undergoing chemotherapy during a COVID outbreak. We use age-related case fatality rates as a basis for estimating risk, and use previous data from risk of death during influenza outbreaks to estimate the additional risk associated with chemotherapy. We use data from randomised trials to estimate benefit across a range of curative and palliative settings, and address the balance of benefit against the risk of harm. We then use those data to estimate the impact on national chemotherapy delivery patterns.

INTRODUCTION

The world is experiencing an outbreak of a novel coronavirus known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2; COVID-19) and WHO has recently declared the disease a pandemic. Although the overall case fatality rate is lower than some other recent respiratory infections, the widespread pattern of infection puts many more people at risk¹. Patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments².

There are not yet any clear models to guide risk predictions in patients infected with COVID-19. One report by the Centres for Disease Control in China provided numbers of patients and fatalities divided by age, and by comorbidities. However, there was no cross-tabulation of factors, and so it is not clear how many patients in each age group had each comorbidity, nor how the risks associated with those co-morbidities interact with each other³. There is one small series of 18 patients with cancer, which suggests higher risks of intubation or death, but it is so small it difficult to draw robust conclusions, and the authors' conclusions have been criticised⁴. One other study suggests patients with a history of cancer have a higher risk of becoming infected with COVID. The data from CDC China have been used to simulate a population and then develop a risk model based on that simulated population⁵; Although a useful step, it almost certainly leads to "double counting" of risk (i.e. the increased risk of death in older patients and in those with hypertension is related, as hypertension is commoner in the elderly). Data from patients admitted to hospital show an increased risk of death in older patients⁶.

Previous work in seasonal and pandemic influenza has highlighted that a history of cancer receiving chemotherapy within the last 6 months (ref) or immunosuppression (including chemotherapy)⁷⁻¹⁰ were all risks for death in patients infected with pandemic influenza. The risk estimates vary considerably, with odds ratios ranging from 3 to 12.

The available data indicates a strong age effect in the risk of death from COVID-19. There is probably an increased risk of death in patients with comorbidities, of which cancer is one. There are several studies indicating an increased risk of death in patients with cancer who are infected during influenza pandemics. There is limited data to suggest that patients who have recently received chemotherapy may be at increased risk of death from influenza infection. There are no good models to estimate the risk of death in patients who have chemotherapy and acquire COVID infection, but there are parameters from previous viral pandemics, all of which point to a higher risk of death in patients with cancer or those who are immunosuppressed.

Medical practice does not always require precise estimates of risk. If a decision is binary (i.e. treat/ don't treat) then what we require is an estimate of risk that is good enough to make a decision, rather than being precise. The majority of adult chemotherapy offers modest benefit, particularly in patients with solid tumours. Although there are some diseases where chemotherapy offers very large benefits (e.g. germ cell tumours), the majority of patients derive modest benefit, and in the context of a COVID pandemic, the risks may outweigh the benefits. The immunosuppressive effect of chemotherapy may last for a considerable period of time, exposing patients to risk as infection rates rise. There has been little guidance so far: to date, we are aware only of individual centres publishing general information¹¹, and one charity-led initiative in the UK¹².

In this paper we estimate risks of death in patients who undergo chemotherapy and become infected with COVID. We use that model to illustrate several common chemotherapy scenarios

in both adjuvant and palliative scenarios, and provide code online for others to use. We use national chemotherapy data to estimate the number of patients whose treatment might be affected by these decisions.

MODELLING

We used combined data from the China CDC³, Italian public health authorities¹³ and a COVID outbreak on a cruiseship¹⁴ to estimate case fatality rates (CFR) by age group. We identified studies that estimated risk of harms (including death) in patients with cancer or immunosuppression during influenza outbreaks and extracted data on risks of harm. We explored sensitivity by constructing models using central estimates of risk of harm and most optimistic estimates. We constructed clinical scenarios by identifying key clinical trials in the curative and palliative setting in five sentinel tumours sites (breast, lung, colorectal, prostate and brain), and extracted data on absolute benefit from treatment in those trials. For trials in the curative setting, we extracted data on the absolute difference in OS at the timepoint specified by the trial (typically 3 or 5 years). For palliative chemotherapy trials, we extracted data on the difference in absolute survival at 3, 6 and 12 month timepoints. We then compared the improvement in absolute survival from treatment with the potential harm if COVID infected, and visualised these results.

RESULTS

There is a clear impact of age on risk of death (Table 1). Data on risk of death with cancer in the context of influenza infection suggests an increased risk in the range of 3 - 12 fold. We chose the lowest reported odds ratio (3.67) as our optimistic estimate of risk. Combined with our age-based CFRs, these lead to estimates of risk by age in patients receiving chemotherapy who become COVID infected (Table 2). We summarise these results in figure 1, highlighting some potential benefit thresholds (3%, 5%, 10%) that are typically seen in adult solid tumour chemotherapy. Of the 9 scenarios, risk of death if COVID infected was higher than expected benefit in six of the seven, balanced in one and favoured chemotherapy in two cases. Readers can explore these data in a small associated program, available at <https://gitlab.com/computational.oncology/covidcancerrisk>

Although the instantaneous risk of COVID infection is small, the risk over the entire duration is likely to be considerable. While we can assume that the risk of infection in patients is the same as the expected population-level infection rate, population level infection may take many months to occur. A more time limited horizon is given by estimating the number of cases of time, and integrating that number.

DISCUSSION

It is clear that age is a significant risk factor for death in patients infected with COVID-19. In both this and previous viral pandemics, other comorbidities have been additional risk factors. There is reasonable evidence to suggest that patients who have cancer are probably at higher risk of death, and it seems unlikely that administration of chemotherapy will reduce that risk fur-

Age (years)	China		Italy		Diamond Princess cruise ship		Combined				
	Cases	CFR(%)	Cases	CFR(%)	Cases	CFR(%)	Cases	Deaths	CFR(%)	CI95%	
0-9	416	-	63	0	1	0	480	0	-	-	-
10-19	549	0.2	118	0	5	0	672	1	0.15	-0.14	0.44
20-29	3619	0.2	511	0	28	0	4158	7	0.17	0.04	0.29
30-39	7600	0.2	819	0.2	34	0	8453	19	0.22	0.12	0.33
40-49	8571	0.4	1523	0.2	27	0	10121	39	0.39	0.26	0.51
50-59	10008	1.3	2480	0.8	59	0	12547	144	1.15	0.96	1.33
60-69	8583	3.6	2421	2.7	177	0	11181	374	3.34	3.01	3.68
70-79	3918	8.0	2849	9.6	234	2.56	7001	592	8.46	7.80	9.11
>80	1408	14.8	2533	17.0	54	1.85	3995	639	15.99	14.86	17.13
Not reported	-	-	565	3.2	-	-	565	18	-	-	-
Total	44672	2.3	13882	5.8	619	1.13	59173	1833	3.10	2.96	3.24

Table 1. Case fatality rates by age group for available international data

Age	Cases	Deaths	CFR(%)	CFR with Chemotherapy (%)
0-9	480	0	-	-
10-19	672	1	0.086	0.23
20-29	4158	7	0.017	0.45
30-39	8453	19	0.22	0.6
40-49	10121	39	0.39	1.0
50-59	12547	144	1.15	2.9
60-69	11181	374	3.34	7.9
70-79	7001	592	8.46	16.9
>80	3995	639	15.99	15
Not reported	565	18	-	-
Total	59173	1833	3.10	7.6

Table 2. Estimated case fatality rates by age group with chemotherapy

ther, although providing an exact estimate of risk is difficult, and not yet possible. Due to the epidemic nature of the disease, with exponential growth in cases, while the risks today may seem small, the predicted risks over the next few months are very much higher.

There is consistent evidence to suggest that patients with a history of cancer are at higher risk of adverse outcomes when infected with COVID-19. A study of 138 patients with a baseline risk of ITU admission of 26%, 40% of those with a history of cancer required ITU admission²⁴, but included only 10 patients with cancer. A review of 18 cancer patients who developed COVID-19 infection showed a higher risk of harm (defined as requiring ventilation in ITU or death) 7/18 (39%) than the general population 124/1572 (8%). 12 of these 18 were being followed up after surgery, while the 4 who had undergone chemotherapy or surgery within the last month had higher risk still⁴. There is some evidence that patients with cancer might be at higher risk of infection²⁵.




Figure 1. Optimistic model case fatality rates in patients with cancer infected with COVID-19, by age. Dashed lines represent common levels of benefit from chemotherapy in percent.

It is worth noting that the risks associated with cancer are based on small samples: aside from the two studies above (which included a total of 28 patients with cancer), the original dataset included only 107 patients with cancer. In contrast, the data on increased risk in older patients is much more robust, although the existing models do not adequately distinguish between risk due to age and that due to increased presence of co-morbidities in older patients.

Our model provides two estimates of risk in order to inform decisions. This model is based on the best available data, but is imperfect. We hope that better models will soon be available, but in the meantime oncologists need to make decisions about chemotherapy. Our model only requires oncologists to be able to specify the absolute improvement in overall survival, and then balance that against the predicted risk if the patient becomes COVID-19 infected. Most older adult patients with solid tumours have a level of elevated risk such that, even if we assume lower rates of infection and case fatality rates, the harms are likely to outweigh the benefits for most chemotherapy in most patients. The uncertainty about whether increased risk is due to having

Tumour Site	Case history	Chemotherapy Regime	Evidence	Outcome	CFR risk
ADJUVANT					
Colorectal	44yo male with resected stage III node positive AdenoCa of Colon.	5FU/ Eoloic Acid / Oxaliplatin .	MOSAIC	10 year OS 59.0% vs. 67.1%; HR 0.80	CFR of 0.05. Benefit of chemotherapy outweighs risk
Breast	60yo female with resected Stage IIB adenocarcinoma of the breast.	EC-T Epirubicin /cyclophosphamide/ Taxace .	Early Breast Cancer Trialists' Collaborative Group (EBCTCG)	Reduced overall mortality from 40 to 35% (RR 0.84; 95% CI 0.78-0.91) OS at 6 months: 84.2 to 86.3%	CFR of 0.18. Risk outweighs potential benefit from chemotherapy.
Lung	66yo male with resected Stage IIIA NSCLC .	Cisplatin-based doublet	LACE meta-analysis	Decreased risk of death of 5.4% at 5 years vs. no chemotherapy; HR 0.89, 95%CI 0.82-0.96	CFR of 0.18. Risk outweighs potential benefit from chemotherapy.
Brain	57yo male with WHO Grade IV resected GBM; MGMT Methylated	Temozolamide (150mg/m ²)	Stupp et al 2009	14.6 vs. 12.1 months; HR 0.63, 95% CI 0.53-0.75. 2 year survival: 24% vs. 46% methylated group	CFR of 0.1. Benefit of chemotherapy outweighs risk
PALLIATIVE					
Colorectal	73yo male, metastatic colorectal AdenoCa Colon	5FU/ Eoloic Acid / Oxaliplatin .	De Gramont et al	OS 16.2 vs. 14.7 months; Grade 3 or 4 neutropaenia 41.7% vs. 5.3%	CFR of 0.22. Risk outweighs potential benefit from chemotherapy.
Breast	68yo female, ER+ve , HER2-ve metastatic breast cancer	Capecitabine	ANZBCTG – capecitabine vs CMF	OS 22 months vs. 18 months Probability OS at 18 months: 0.45 vs. 0.52	CFR of 0.18. Risk outweighs potential benefit from chemotherapy.
Prostate	75yo male with metastatic prostate cancer	Docetaxel and prednisolone	Tannock 2004	HR for death 0.76 (95% CI, 0.62 to 0.94; P=0.009). Median survival 18.9 vs. 16.5 months OS @ 3 months: 96% OS @ 6 months: 88% grade 3 or 4 neutropaenia = 9.6% febrile neutropaenia: <1%	CFR of 0.22. Risk outweighs potential benefit from chemotherapy.
Lung	73yo female; Metastatic non-small cell carcinoma;	Platinum-based doublet regime	NSCLC Collaborative Group... supportive care vs SC + CTx .	HR, 0.77; 95% CI, 0.71 to 0.83; 9 month OS 20 to 29%. 3 month OS: Probability of survival 0.65 to 0.75 6 month OS: 0.42 to 0.58	CFR of 0.22. Risk outweighs potential benefit from chemotherapy.
Lung	66yo female metastatic non-squamous NSCLC, PDL1<50%, >1%	Platinum, pemetrexed and pembrolizumab .	Keynote 189	OS @ 12 months: 69.2% vs 49.4% OS@ 3 months: 89% to 92% OS@ 6 months: 72% to 87% Grade 3,4,5 neutropaenia: 15.8% in pem group vs. 11.9% in platt+pem .	CFR of 0.18. Risk and benefit of chemotherapy balanced.

Figure 2. Scenarios exploring absolute survival benefit and potential risks in a variety of common chemotherapy settings^{15–23}

cancer, or receiving chemotherapy is of secondary importance. If it is due to having cancer, then we would suggest that receiving chemotherapy would simple increase in further. We would stress that any additional risk from administering chemotherapy is likely to be a multiplier on the risks seen here; thus small relative risks may translate to large changes in absolute risk for some patients. We have also assumed that both harm and benefits accrue over the same time period, whereas in reality, most improvements in cancer survival with chemotherapy are calculated at 2 and 5 years. For patients undergoing palliative chemotherapy, it is probably more reasonable to assume that the risks and harms accrue over a similar time period; for those having adjuvant treatment, where chemotherapy increases the chance of cure, the benefits may accrue over a much longer time period. In this sense, treatment is more valuable (in that it leads to more years of life) but harm from treatment also weighs more heavily.

Palliative chemotherapy may be given primarily for symptom relief, rather than to improve survival. Nonetheless, the risks of death are still elevated. Although radiotherapy incurs some of the same risks associated with hospital attendance, there are some situations where palliative radiotherapy might be substituted for chemotherapy with a reasonable expectation of it being safer. Decisions about continuing chemotherapy in those established on treatment are more diffi-

cult, as the relative benefits of (for example) longer vs. shorter courses of adjuvant chemotherapy have often not been explored in randomised trials. Where they have been, it may be worth exploring the incremental benefit in light of the increased risk. At the very least, because informed consent relies in part on understanding the balance between risk and benefit, given that the risk has changed, we would suggest confirming informed consent in patients who are continuing on chemotherapy. Non-cytotoxic agents (e.g. immunotherapy and bisphosphonates) almost certainly have different risk profiles. Nonetheless, there are some common concerns with patients receiving cytotoxic agents, in that they still attend hospitals, and may not be able to access care if services are overwhelmed.

The most striking finding is that under a range of conditions, most cancer patients are at $> 5\%$ risk of death if infected with COVID-19. It is notable that the 5% is greater than or equal to the benefit from most adjuvant chemotherapy for adult solid tumours. Although we accept that exact negative impact of COVID-19 in subgroups remains unclear, previous data during outbreaks of seasonal respiratory viral infections suggests that they are associated with an approximate doubling in risk. However, in contrast to outbreaks of seasonal infections, the majority of the population is expected to be infected with COVID-19 over a short-time period (3 - 6 months), there is no pre-existing immunity or vaccine, and the case-fatality rate is approximately 5 fold higher. For those reasons, decision-making in seasonal viral outbreaks does not directly transfer to the COVID-19 pandemic. Decisions about initiating or continuing cytotoxic chemotherapy in the context of a COVID pandemic need to be made carefully, and in light of the available data.

Acknowledgments

Our thanks to Katie Spencer and Alice Dewdney for highlighting errors in calculations in an earlier version; to Alison Falconer for discussions about palliative chemotherapy; to those who commented on an earlier draft, and to all of those who have provided data on which this work is based.

This work is licensed under a creative commons CC BY-NC-ND license

REFERENCES

1. Zunyou Wu and Jennifer M McGoogan. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*, 2 2020. ISSN 1538-3598. doi: 10.1001/jama.2020.2648. URL <http://www.ncbi.nlm.nih.gov/pubmed/32091533>.
2. Mini Kamboj and Kent A. Sepkowitz. Nosocomial infections in patients with cancer, 6 2009. ISSN 14702045. URL <http://www.ncbi.nlm.nih.gov/pubmed/19482247>.
3. CDC CHINA. Coronavirus Statistics, 2020. URL <http://rs.yiigle.com/yufabiao/1181998.htm>.
4. Allison Landman, Laura Feetham, and Daniel Stuckey. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncology*, 21:335–337, 2020. doi: 10.1016/j.lancet.2020.02.24.20027268. URL <https://doi.org/10.1016/j.lancet.2020.02.24.20027268>.
5. F Caramelo, ; N Ferreira, and ; B Oliveiros. Estimation of risk factors for COVID-19 mortality - preliminary results. doi: 10.1101/2020.02.24.20027268. URL <https://doi.org/10.1101/2020.02.24.20027268>.
6. Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu, Lulu Guan, Yuan Wei, Hui Li, Xudong Wu, Jiuyang Xu, Shengjin Tu, Yi Zhang, Hua Chen, and Bin Cao. Articles Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, 2020. doi: 10.1016/S0140-6736(20)30566-3. URL [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
7. Masato Takeuchi, Hideo Yasunaga, Hiromasa Horiguchi, and Shinya Matsuda. Clinical features of infants hospitalized for 2009 pandemic influenza A (H1N1) in Japan: Analysis using a national hospital discharge database. *Pediatric Infectious Disease Journal*, 31(4):368–372, 4 2012. ISSN 08913668. doi: 10.1097/INF.0b013e318241ad06.
8. Catherine D. Cooksley, Elenir B.C. Avritscher, Benjamin N. Bekele, Kenneth V. Rolston, Jane M. Geraci, and Linda S. Elting. Epidemiology and outcomes of serious influenza-related infections in the cancer population. *Cancer*, 104(3):618–628, 8 2005. ISSN 0008543X. doi: 10.1002/cncr.21203.
9. Ana Freitas Ribeiro, Alessandra Cristina Guedes Pellini, Beatriz Yuko Kitagawa, Daniel Marques, Geraldine Madalosso, Gerrita De Cassia Nogueira Figueira, João Fred, Ricardo Kerti Mangabeira Albernaz, Telma Regina Marques Pinto Carvalhanas, and Dirce Maria Trevisan Zanetta. Risk factors for death from influenza a (H1N1)pdm09, State of São Paulo, Brazil, 2009. *PLoS ONE*, 10(3), 3 2015. ISSN 19326203. doi: 10.1371/journal.pone.0118772.
10. Inge M.L. Ahout, Ria L.A. Philipsen, Mariëtte Las, Meryem Baysan, Frank Brus, Jeanette C. Rahamat-Langendoen, Nel Roeleveld, Pieter L. Fraaij, Albert D.M.E. Osterhaus, Gerben Ferwerda, and Ronald De Groot. Nationwide Study on the Course of Influenza A

- (H1N1) Infections in Hospitalized Children in the Netherlands during the Pandemic 2009-2010. *Pediatric Infectious Disease Journal*, 37(12):E283–E291, 12 2018. ISSN 15320987. doi: 10.1097/INF.0000000000002177.
11. Cynthia Demarco. COVID-19 symptoms, screening and testing: Insight for cancer patients and caregivers. URL <https://www.mdanderson.org/publications/cancerwise/covid-19-symptoms-and-screening-testing-insight-for-cancer-patients-and-caregivers.h00-159380367.html>.
 12. Coronavirus advice for cancer patients | COVID-19 | Teenage Cancer Trust. URL <https://www.teenagecancertrust.org/get-help/coronavirus>.
 13. The COVID-19 Task force of the Department of Infectious Diseases and the IT Service. Integrated surveillance of COVID-19 in Italy. Technical report, Istituto Superiore di Sanità, 2020. URL https://www.epicentro.iss.it/coronavirus/bollettino/covid-19-infografica_eng.pdf.
 14. Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, Cmmid Covid, working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, and Adam J Kucharski. Estimating the infection and case fatality ratio for COVID-19 using age-adjusted data from the outbreak on the Diamond Princess cruise ship. doi: 10.1101/2020.03.05.20031773. URL <https://doi.org/10.1101/2020.03.05.20031773>.
 15. Thierry André, Armand de Gramont, Dewi Vernerey, Benoist Chibaudel, Franck Bonnetain, Annemiläi Tijeras-Raballand, Aurelie Scriva, Tamas Hickish, Josep Tabernero, Jean Luc Van Laethem, Maria Banzi, Eduard Maartense, Einat Shmueli, Goran U Carlsson, Werner Scheithauer, Demetris Papamichael, Marcus Möehler, Stefania Landolfi, Pieter Demetter, Soudhir Colote, Christophe Tournigand, Christophe Louvet, Alex Duval, Jean-François Fléjou, and Aimery de Gramont. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 33(35):4176–87, 12 2015. ISSN 1527-7755. doi: 10.1200/JCO.2015.63.4238. URL <http://www.ncbi.nlm.nih.gov/pubmed/26527776>.
 16. K. Albain, S. Anderson, R. Arriagada, W. Barlow, J. Bergh, J. Bliss, M. Buyse, D. Cameron, E. Carrasco, M. Clarke, C. Correa, A. Coates, R. Collins, J. Costantino, D. Cutter, J. Cuzick, S. Darby, N. Davidson, C. Davies, K. Davies, A. Delmestri, A. Di Leo, M. Dowsett, P. Elphinstone, V. Evans, M. Ewertz, R. Gelber, L. Gettins, C. Geyer, A. Goldhirsch, J. Godwin, R. Gray, C. Gregory, D. Hayes, C. Hill, J. Ingle, R. Jakesz, S. James, M. Kaufmann, A. Kerr, E. MacKinnon, P. McGale, T. McHugh, L. Norton, Y. Ohashi, S. Paik, H. C. Pan, E. Perez, R. Peto, M. Piccart, L. Pierce, K. Pritchard, G. Pruneri, V. Raina, P. Ravdin, J. Robertson, E. Rutgers, Y. F. Shao, S. Swain, C. Taylor, P. Valagussa, G. Viale, T. Whelan, E. Winer, Y. Wang, and W. Wood. Comparisons between different polychemotherapy

- regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. *The Lancet*, 379(9814):432–444, 2 2012. ISSN 1474547X. doi: 10.1016/S0140-6736(11)61625-5.
17. Jean Pierre Pignon, H el ene Tribodet, Giorgio V. Scagliotti, Jean Yves Douillard, Frances A. Shepherd, Richard J. Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen G. Spiro, Estelle Rolland, Roldano Fossati, Delphine Aubert, Keyue Ding, David Waller, and Thierry Le Chevalier. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. *Journal of Clinical Oncology*, 26(21):3552–3559, 7 2008. ISSN 0732183X. doi: 10.1200/JCO.2007.13.9030. URL <http://www.ncbi.nlm.nih.gov/pubmed/18506026>.
 18. Roger Stupp, Monika E. Hegi, Warren P. Mason, Martin J. van den Bent, Martin JB Taphoorn, Robert C. Janzer, Samuel K. Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger, Peter Hau, Alba A. Brandes, Johanna Gijtenbeek, Christine Marosi, Charles J. Vecht, Karima Mokhtari, Pieter Wesseling, Salvador Villa, Elizabeth Eisenhauer, Thierry Gorlia, Michael Weller, Denis Lacombe, J. Gregory Cairncross, and Ren e Olivier Mirimanoff. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *The Lancet Oncology*, 10(5):459–466, 2009. ISSN 14702045. doi: 10.1016/S1470-2045(09)70025-7.
 19. A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. De Braud, C. Wilson, F. Morvan, and A. Bonetti. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *Journal of Clinical Oncology*, 18(16):2938–2947, 2000. ISSN 0732183X. doi: 10.1200/JCO.2000.18.16.2938.
 20. Martin R. Stockler, Vernon J. Harvey, Prudence A. Francis, Michael J. Byrne, Stephen P. Ackland, Bernie Fitzharris, Guy Van Hazel, Nicholas R.C. Wilcken, Peter S. Grimison, Anna K. Nowak, M. Corona Gainford, Akiko Fong, Lisa Paksec, Tatiana Sourjina, Diana Zannino, Val Gebiski, R. John Simes, John F. Forbes, and Alan S. Coates. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. *Journal of Clinical Oncology*, 29(34):4498–4504, 12 2011. ISSN 0732183X. doi: 10.1200/JCO.2010.33.9101. URL <http://www.ncbi.nlm.nih.gov/pubmed/22025143>.
 21. Ian F. Tannock, Ronald De Wit, William R. Berry, Jozsef Horti, Anna Pluzanska, Kim N. Chi, Stephane Oudard, Christine Th eodore, Nicholas D. James, Ingela Turesson, Mark A. Rosenthal, and Mario A. Eisenberger. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *New England Journal of Medicine*, 351(15):1502–1512, 10 2004. ISSN 00284793. doi: 10.1056/NEJMoa040720.
 22. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care

improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 26(28):4617–25, 10 2008. ISSN 1527-7755. doi: 10.1200/JCO.2008.17.7162. URL <http://www.ncbi.nlm.nih.gov/pubmed/18678835><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2653127>.

23. Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell, Susanna Y.-S. Cheng, Helge G Bischoff, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Rina Hui, Edward B Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M Catherine Pietanza, and Marina C Garassino. KEYNOTE 189 (adeno): Pembrolizumab plus Chemotherapy (carbo/pemetrexed) in Metastatic Non–Small-Cell Lung Cancer (adeno). *New England Journal of Medicine*, 378(22):NEJMoa1801005, 5 2018. ISSN 0028-4793. doi: 10.1056/NEJMoa1801005. URL <http://www.nejm.org/doi/10.1056/NEJMoa1801005>.
24. Dawei Wang, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang, Binbin Wang, Hui Xiang, Zhenshun Cheng, Yong Xiong, Yan Zhao, Yirong Li, Xinghuan Wang, and Zhiyong Peng. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - Journal of the American Medical Association*, pages 1–9, 2020. ISSN 15383598. doi: 10.1001/jama.2020.1585.
25. Jing Yu, Ouyang Wen, Melvin L.K. Chua, and Xie Conghua. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. *Medrxiv*, 2020. doi: 10.1101/2020.02.22.20025320d.